The team aims to fully commercialize the 28-biomarker panel for military veterans and civilians who show early symptoms of post-traumatic stress disorder.
The firm said that its rapid point-of-care test enables immediate drug adjustments by measuring levels of clozapine, an antipsychotic drug, in a finger prick of blood.
